Essais cliniques près de Calgary : maladie d'alzheimer

Cannabidiol Medication Intervention Trial

Recruiting nowPhase 25 sites

CALM-IT is a Randomized, double-blind, placebo-controlled cross-over clinical trial. Safety and efficacy of cannabidiol (CBD) capsules assessed for managing agitation in patients with AD and to identify novel biomarkers of agitation severit…

A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)

Recruiting nowPhase 3154 sites

This is a Phase 3, randomized, double-blind, placebo-controlled, parallel group study to evaluate the safety and efficacy of KarXT in male and female subjects who are aged 55 to 90 years and have mild to severe Alzheimer's Disease (AD) with…

Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)

Recruiting nowPhase 3429 sites

This is a Phase 3 global, multicenter, 52-week, open-label extension (OLE) rollover study for subjects completing study CN012-0026, CN012-0027 or CN012-0056. Subjects (randomized or non-randomized) who complete the 38-week CN012-0026 study,…

Aerobic Exercise for Older Adults at Increased Risk of Alzheimer's Disease and Related Dementias

Recruiting now1 site

The estimated annual cost of dementia in Canada is $15 billion, with a projected cumulative economic burden of $800 billion by 2038. Effective prevention of dementia at a population level will need to include lifestyle factors such as promo…

Nabilone for Agitation Blinded Intervention Trial

Recruiting nowPhase 36 sites

This study will look at whether nabilone is an effective treatment for agitation in Alzheimer's disease (AD) patients. Agitation is highly prevalent in patients with AD and is one of the most distressing and challenging-to-treat symptoms. A…

Comprehensive Assessment of Neurodegeneration and Dementia

Recruiting now19 sites

This is a longitudinal observational study recruiting individuals between the ages of 50 and 90 with different types of dementia as well as a comparison group without cognitive deficits. Participants are/will be recruited at sites across Ca…

PROMIS and Mobility Evaluation in Sarcoma Patients

Recruiting now4 sites

The goal of this is to validate the Patient-Reported Outcomes Measurement Information System (PROMIS) in sarcoma patients undergoing surgery, and to evaluate a novel smartphone app for collecting mobility data. The goals of the study includ…

Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant

Recruiting nowPhase 3103 sites

Transthyretin amyloidosis (ATTR) is a disease where the normally occurring transthyretin (TTR) protein falls apart and forms amyloid, a sticky plaque-like substance that accumulates in different organs in the body and can cause damage to th…

Questions fréquentes

Comment trouver un essai clinique (maladie d'alzheimer) près de chez moi au Canada ?

Utilisez la recherche gratuite de Beacon : entrez « maladie d'alzheimer », votre âge et votre lieu, et vous verrez les essais en recrutement triés par distance, chacun expliqué en langage clair — y compris les sites juste de l'autre côté de la frontière américaine. Beacon interroge le registre officiel complet et n'exige jamais de compte.

Participer à un essai clinique coûte-t-il de l'argent ?

Le traitement à l'étude et les examens liés à l'étude sont habituellement fournis sans frais, et certains essais aident avec les déplacements. Au Canada, votre régime provincial d'assurance maladie continue de couvrir vos soins courants — confirmez toujours les détails avec l'équipe de l'étude.

Puis-je quitter un essai clinique après y avoir adhéré ?

Oui. La participation est toujours volontaire et vous pouvez quitter un essai à tout moment, pour n'importe quelle raison, sans perdre vos soins médicaux habituels.

Suis-je admissible à ces essais ?

Chaque essai a ses propres critères d'admissibilité. Beacon traduit les critères de chaque essai en une liste en langage clair que vous pouvez passer en revue et apporter à votre médecin — seule l'équipe de l'étude peut confirmer votre admissibilité.